Joshi Alumkal, MD, discusses treatment options for patients with metastatic castrate-resistant prostate cancer harboring homologous recombination deficient alterations, including PARP inhibitors.
Jules Lin, MD, discusses how approaches to surgical intervention in non–small cell lung cancer may have shifted with the increasing use of targeted therapy and immunotherapies in the adjuvant and neoadjuvant setting.
Ulka Nitin Vaishampayan, MBBS, discusses the need for improved identification of patients with homologous recombination repair (HRR) gene–mutated metastatic castration-resistant prostate cancer who may benefit from treatment with talazoparib and enzalutamide.
A broad discussion on emerging therapeutic targets in metastatic castration-resistant prostate cancer and where they may fall within the treatment landscape.
Key opinion leaders share insight to novel combination strategies and clinical trials focused on radioligand therapy in metastatic castration-resistant prostate cancer.
Continuing their segment on radioligand therapy in metastatic castration-resistant prostate cancer, panelists highlight data behind use of radium-223.
Ulka Nitin Vaishampayan, MBBS, discusses factors to consider for choosing between immuno-oncology/immuno-oncology and VEGF TKI/immuno-oncology combinations for the frontline treatment of patients with renal cell carcinoma, areas of ongoing research in this disease, and treatment updates across the prostate cancer spectrum.
Ulka Nitin Vaishampayan, MBBS, discusses patient factors to consider when choosing between apalutamide, enzalutamide, and darolutamide for the treatment of patients with non-metastatic castration resistant prostate cancer.
Focused discussion on the role of lutetium-177–PSMA-617 as radioligand therapy in patients with metastatic castration-resistant prostate cancer.
Key opinion leaders in metastatic castration-resistant prostate cancer management review a subset of clinical trials focused on combination strategies with PARP inhibitors.
Comprehensive insight to key treatment modalities for patients with nonmetastatic castration-resistant prostate cancer and how to select amongst them.
Angel Qin, MD, contextualizes the non–small cell lung cancer ADAURA trial, in which patients with EGFR-mutated non–small cell lung cancer who received adjuvant therapy with osimertinib achieved a 5-year overall survival rate of 85% vs 73% in those who received placebo.
A brief conversation on negative clinical trial readouts and how they may help to inform optimal treatment pathways for patients with metastatic hormone-sensitive prostate cancer.
Following their discussion on systemic therapy, expert panelists consider the value of locoregional therapy for a subset of patients with metastatic hormone-sensitive prostate cancer.
Lori J. Pierce, MD harbored a love for science and a general desire to know things, and she was not shy about asking questions. She displayed a gift for math early in life, a trait she and her older sister, Karen, both inherited from their father, Melvin H. Pierce.